ArticleScientific reports2022
Multicentre study on the reproducibility of MALDI-TOF MS for nontuberculous mycobacteria identification.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Prevalence of non-tuberculous mycobacteria in various regions of the Russian Federation.BMC infectious diseases · 2026Pooled it
- Protein Extraction From Mycobacterium spp. for Identification by MALDI-TOF Mass Spectrometry.Current protocols · 2026Article
- Clinical peptidomics for respiratory diseases: matrices, workflows, and translation towards treatable traits, with a focus on COPD.Clinical proteomics · 2026Review
- DisseminatedJournal of clinical tuberculosis and other mycobacterial diseases · 2026Article
- Pulmonary disease caused byNew microbes and new infections · 2025Article
- A rapid and simple MALDI-TOF MS lipid profiling method for differentiatingJournal of clinical microbiology · 2025Article
- Comparative analysis of microbial contamination in diesel fuels using MALDI-TOF MS.Scientific reports · 2025Article
- Comparative evaluation of MALDI-ToF mass spectrometry and Sanger sequencing of theFrontiers in cellular and infection microbiology · 2025Article
- Microbiological profile of slow-growing non-tuberculous mycobacteria species other thanFrontiers in microbiology · 2025Article
- A practical guide to the diagnosis and management of suspected Non-tuberculous Mycobacterial Pulmonary Disease (NTM-PD) in the United Kingdom.NPJ primary care respiratory medicine · 2024Article
- Source-to-tap investigation of the occurrence of nontuberculous mycobacteria in a full-scale chloraminated drinking water system.Applied and environmental microbiology · 2024Article
- Incorporating direct molecular diagnostics in management algorithms for nontuberculous mycobacteria: Is it high time?IJID regions · 2024Review
- MALDI-TOF MS: A Reliable Tool in the Real Life of the Clinical Microbiology Laboratory.Microorganisms · 2024Review
- Non-tuberculous mycobacterial pulmonary disease (NTM-PD): Epidemiology, diagnosis and multidisciplinary management.Clinical medicine (London, England) · 2024Review
- Article
- Improved MALDI-TOF MS Identification ofMicroorganisms · 2023Article
- MGIT-seq for the Identification of Nontuberculous Mycobacteria and Drug Resistance: a Prospective Study.Journal of clinical microbiology · 2023Article
- Identification of Nocardia and non-tuberculous Mycobacterium species by MALDI-TOF MS using the VITEK MS coupled to IVD and RUO databases.Microbial biotechnology · 2023Article
- MGIT Enriched Shotgun Metagenomics for Routine Identification of Nontuberculous Mycobacteria: a Route to Personalized Health Care.Journal of clinical microbiology · 2023Article
- Identification of Mycobacterium abscessus Subspecies by MALDI-TOF Mass Spectrometry and Machine Learning.Journal of clinical microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 16 institutions in 9 countries.
Funding
Abstract
The ability of MALDI-TOF for the identification of nontuberculous mycobacteria (NTM) has improved recently thanks to updated databases and optimized protein extraction procedures. Few multicentre studies on the reproducibility of MALDI-TOF have been performed so far, none on mycobacteria. The aim of this study was to evaluate the reproducibility of MALDI-TOF for the identification of NTM in 15 laboratories in 9 European countries. A total of 98 NTM clinical isolates were grown on Löwenstein-Jensen. Biomass was collected in tubes with water and ethanol, anonymized and sent out to the 15 participating laboratories. Isolates were identified using MALDI Biotyper (Bruker Daltonics). Up to 1330 MALDI-TOF identifications were collected in the study. A score ≥ 1.6 was obtained for 100% of isolates in 5 laboratories (68.2-98.6% in the other). Species-level identification provided by MALDI-TOF was 100% correct in 8 centres and 100% correct to complex-level in 12 laboratories. In most cases, the misidentifications obtained were associated with closely related species. The variability observed for a few isolates could be due to variations in the protein extraction procedure or to MALDI-TOF system status in each centre. In conclusion, MALDI-TOF showed to be a highly reproducible method and suitable for its implementation for NTM identification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.